Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study.
Verdegaal E, van der Kooij MK, Visser M, van der Minne C, de Bruin L, Meij P, Terwisscha van Scheltinga A, Welters MJ, Santegoets S, de Miranda N, Roozen I, Liefers GJ, Kapiteijn E, van der Burg SH. Verdegaal E, et al. Among authors: santegoets s. J Immunother Cancer. 2020 Mar;8(1):e000166. doi: 10.1136/jitc-2019-000166. J Immunother Cancer. 2020. PMID: 32238469 Free PMC article. Clinical Trial.
In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line.
Santegoets SJ, Schreurs MW, Masterson AJ, Liu YP, Goletz S, Baumeister H, Kueter EW, Lougheed SM, van den Eertwegh AJ, Scheper RJ, Hooijberg E, de Gruijl TD. Santegoets SJ, et al. Cancer Immunol Immunother. 2006 Dec;55(12):1480-90. doi: 10.1007/s00262-006-0142-x. Epub 2006 Feb 9. Cancer Immunol Immunother. 2006. PMID: 16468034 Free PMC article.
Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus.
Hangalapura BN, Oosterhoff D, Aggarwal S, Wijnands PG, van de Ven R, Santegoets SJ, van den Tol MP, Hooijberg E, Pereboev A, van den Eertwegh AJ, Curiel DT, Scheper RJ, de Gruijl TD. Hangalapura BN, et al. Among authors: santegoets sj. J Immunother. 2010 Sep;33(7):706-15. doi: 10.1097/CJI.0b013e3181eccbd4. J Immunother. 2010. PMID: 20664356
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K, Sacks N, Hege K, Lowy I, Cuillerot JM, von Blomberg BM, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, de Gruijl TD. Santegoets SJ, et al. Cancer Immunol Immunother. 2013 Feb;62(2):245-56. doi: 10.1007/s00262-012-1330-5. Epub 2012 Aug 10. Cancer Immunol Immunother. 2013. PMID: 22878899 Free PMC article. Clinical Trial.
The Thirteenth International Conference on Progress in Vaccination Against Cancer (PIVAC-13), October 2-4, 2013, Amsterdam, The Netherlands: the current standing of anti-tumor immunotherapeutic approaches.
Melief SM, Visconti VV, Doorduijn EM, Santegoets SJ. Melief SM, et al. Cancer Immunol Immunother. 2014 Oct;63(10):1105-12. doi: 10.1007/s00262-014-1532-0. Epub 2014 Mar 12. Cancer Immunol Immunother. 2014. PMID: 24619351 Free PMC article. No abstract available.
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.
Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, Scheffold A, Shevach EM, Staats J, Taskén K, Whiteside TL, Kroep JR, Welters MJ, van der Burg SH. Santegoets SJ, et al. Cancer Immunol Immunother. 2015 Oct;64(10):1271-86. doi: 10.1007/s00262-015-1729-x. Epub 2015 Jun 28. Cancer Immunol Immunother. 2015. PMID: 26122357 Free PMC article.
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, Welters MJ, van der Burg SH, Kroep JR. Dijkgraaf EM, et al. Among authors: santegoets sj. Ann Oncol. 2015 Oct;26(10):2141-9. doi: 10.1093/annonc/mdv309. Epub 2015 Jul 27. Ann Oncol. 2015. PMID: 26216383 Free article. Clinical Trial.
A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH. Dijkgraaf EM, et al. Oncotarget. 2015 Oct 13;6(31):32228-43. doi: 10.18632/oncotarget.4772. Oncotarget. 2015. PMID: 26334096 Free PMC article. Clinical Trial.
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.
Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, van Poelgeest MI, Kenter GG, Kroep JR, Burggraaf J, Melief CJ, van der Burg SH. Welters MJ, et al. Among authors: santegoets sj. Sci Transl Med. 2016 Apr 13;8(334):334ra52. doi: 10.1126/scitranslmed.aad8307. Sci Transl Med. 2016. PMID: 27075626 Clinical Trial.
70 results